Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Stock Quote Today & Recent News Fennec Pharmaceuticals Inc T.FRX

Alternate Symbol(s):  ADHXD

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.


Stock Price Chart (TSX:FRX)

Fundamentals Snapshot (TSX:FRX)

Current News (TSX:FRX)

Fennec Announces Results of Annual Meeting

GlobeNewswire June 14, 2022

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire May 23, 2022

Fennec Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire May 12, 2022

Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK(TM)

GlobeNewswire April 27, 2022

FENC Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Fennec Pharmaceuticals Inc. Investors of Class Action and Last Few Hours to Contact the Firm

Business Wire April 11, 2022

FENC FINAL DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Fennec Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important April 11 Deadline in Securities Class Action - FENC

Newsfile April 11, 2022

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Fennec Investors of a Lead Plaintiff Deadline of April 11, 2022

PR Newswire April 11, 2022

FENC FINAL DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Fennec Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important April 11 Deadline in Securities Class Action - FENC

Newsfile April 10, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fennec Pharmaceuticals Inc. of Class Action Lawsuit and Upcoming Deadline - FENC

Newsfile April 9, 2022

Opinion & Analysis (TSX:FRX)

No current opinion is available.

Bullboard Posts (TSX:FRX)

RE:RE:IS THIRD TIME THE CHARM FOR FENNEC PHARMACEUTICALS?

The obvious solution at this stage is to just sell the darn company (at a discount) to a real pharmaceautical company who  has the...
willyk3 - December 13, 2021

RE:IS THIRD TIME THE CHARM FOR FENNEC PHARMACEUTICALS?

Absolute dud    The fact that they failed at the manufacturing revisions shows that they and their mfg partner  are...
willyk3 - December 9, 2021

IS THIRD TIME THE CHARM FOR FENNEC PHARMACEUTICALS?

$FENC  Fennec Pharmaceuticals (NASDAQ:FENC), a "specialty pharmaceutical company", received a CRL from the FDA for...
AviseAnalytics - December 9, 2021

11.50/18.00

Thats a heck of a spread on the bid ask?  Has my machine gone bonkers?
willyk3 - September 27, 2021

RE:Times a wasting

Resubmission is in!  Is there anyone out there to notice? Guess we still have to hope that they dont fail....with the FDA I am never...
willyk3 - June 22, 2021

Times a wasting

No news at all.  Wonder whats up with that resubmission? Shouldnt financials be out for this quarter? I thought they were reasonably...
willyk3 - March 20, 2021